BioSpace News Archive

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021 at 5:20 p.m. ET. A live webcast of the presentation will be available on t

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that the U.S. Food and Drug Administration (FDA) has granted both rare pediatric disease and orphan drug designations for PRAX-222 for the treatment of SCN2A developmental and epileptic encephalopathy (SCN2A-DEE).

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that CEO Lawrence Blatt, Ph.D., MBA, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 3:40 p.m. ET/12:40pm PT. The presentation will be followed by a virtual Q&A session. A reco

Itamar Medical Ltd. (Nasdaq: ITMR) (TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported preliminary unaudited revenue results for the fourth quarter and full year ended December 31, 2020.

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced the expansion of its commercial organization. Sales Organization Update As part of the Company’s previously announced sales organization optimization initiative, the Company recently expanded the size of its s

DarioHealth Corp., a pioneer in the global digital therapeutics market, announced the appointment of Claudia Rimerman Kraut as Vice President of Broker and Consultant Partnerships.

Almirall, S.A. (BME: ALM), a global biopharmaceutical company based in Barcelona, and Tyris Therapeutics, a next-generation gene therapy company founded by Columbus Venture Partners, have announced a strategic partnership today to tackle orphan dermatological conditions using non-viral gene therapies.

- Phase 3 HDV D-LIVR (Lonafarnib) Planned to Complete Enrollment in 2021 - Phase 3 HDV LIMT-2 (Lambda) Planned to Initiate in 2H21 - Zokinvy™ EMA Approval Expected in 2H21 - Strong Cash Position with ~$176M Pro Forma Cash to Begin 2021

AbSci, a leading synthetic biology company enabling drug discovery and biomanufacturing of next generation biotherapeutics, today announced that Sean McClain , Founder and CEO, will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 7:25 a.m. PT / 10:25 a.m. ET .

Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it will supply the U.S. Centers for Disease Control and Prevention (CDC) with a customized version of Twist SARS-CoV-2 Synthetic RNA Controls for use in the CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay.